Patents by Inventor Su Qian

Su Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPIRO COMPOUND AND MEDICAL USES THEREOF
    Publication number: 20220041616
    Abstract: The present invention relates to a spiro compound and medical uses thereof. Specifically, the present invention relates to a spiro compound represented by the general formula (I), a preparation method thereof, a pharmaceutical composition containing the same, and is used as an acetyl-Coenzyme A carboxylase (ACC) inhibitor and is used for treating diseases associated with ACC activity. Each substituent in the general formula (I) is as defined in description.
    Type: Application
    Filed: November 20, 2019
    Publication date: February 10, 2022
    Inventors: Huijun YIN, Xu YAN, Junge WEN, Weixue TIAN, Qiyong MOU, Ning FU, Jingqian JIANG, Yao WU, Guosheng WU, Xueying FENG, Su QIAN
  • Aryl glycoside compound, preparation method and use thereof
    Patent number: 8980829
    Abstract: Disclosed are an aryl glycoside compound as represented by formula I or formula I?, a pharmaceutically acceptable salt thereof, optical isomer thereof or a prodrug thereof. The present invention relates to a method of preparing said aryl glycoside compound and the use thereof. The aryl glycoside compound of the present invention has an excellent ability on inhibit SGLT activity, especially SGLT2 activity, and is diabetes-fighting medicine with great potential.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: March 17, 2015
    Assignees: Shanghai Yingli Science and Technology Co., Ltd, Shanghai Chempartner Co., Ltd
    Inventors: Zusheng Xu, Su Qian
  • ARYL GLYCOSIDE COMPOUND, PREPARATION METHOD AND USE THEREOF
    Publication number: 20130324464
    Abstract: Disclosed are an aryl glycoside compound as represented by formula I or formular I?, a pharmaceutically acceptable salt thereof, optical isomer thereof or a prodrug thereof. The present invention relates to a method of preparing said aryl glycoside compound and the use thereof The aryl glycoside compound of the present invention has an excellent ability on inhibit SGLT activity, especially SGLT2 activity, and is diabetes-fighting medicine with great potential.
    Type: Application
    Filed: February 17, 2012
    Publication date: December 5, 2013
    Applicants: SHANGHAI CHEMPARTNER CO., LTD, SHANGHAI YINGLI SCIENCE AND TECHNOLOGY CO., LTD
    Inventors: Zusheng Xu, Su Qian
  • Combination Therapy for the Treatment of Obesity
    Publication number: 20080064632
    Abstract: The present invention relates to compositions comprising PYY, PYY3-36, or a PYY agonist, and an anti-obesity agent, useful for the treatment and prevention of obesity and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity and obesity-related disorder in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.
    Type: Application
    Filed: September 22, 2005
    Publication date: March 13, 2008
    Inventors: John Amatruda, Paul Daruwala, Ngozi Erondu, Douglas MacNeil, David Moller, Su Qian
  • MCH1R deficient mice
    Patent number: 7259289
    Abstract: The present invention features viable MCH1R deficient mice. MCH1R deficient mice contain an alteration in one or both MCH1R alleles that substantially reduces expression of a functional MCH1R from the altered allele. Preferably, MCH1R deficient mice are MCH1R ?/? knockout mice.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: August 21, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Su Qian, Donald J. Marsh
  • Agouti-related protein deficient cells, non-human transgenic animals and methods of selecting compounds which regulate energy metabolism
    Publication number: 20050257279
    Abstract: Cells and non-human transgenic animals have been engineered to be deficient in the gene encoding agouti-related protein (AgRP). AgRP deficient transgenic animals have a reduced day time respiratory quotient (RQ), indicating that AgRP is involved in the regulation of energy metabolism, resulting in the reduced usage of fat as an energy source. These AgRP deficient transgenic animals can be used to select for and test potential modulators of AgRP. This data allows for methods of screening for AgRP modulators which regulate energy metabolism and caloric utilization. The disclosure also relates to a NPY/AgRP double knockout mouse which can be used to select for and test potential modulators (e.g., agonists or antagonists) of AgRP and/or NPY.
    Type: Application
    Filed: June 27, 2003
    Publication date: November 17, 2005
    Inventors: Su Qian, Leonardus Van der Ploeg, Howard Chen, Drew Weingarth, Myrna Trumbauer, Joseph Metzger
  • Mch1r deficient mice
    Publication number: 20040128708
    Abstract: The present invention features viable MCH1R deficient mice. MCH1R deficient mice contain an alteration in one or both MCH1R alleles that substantially reduces expression of a functional MCH1R from the altered allele. Preferably, MCH1R deficient mice are MCH1R −/− knockout mice.
    Type: Application
    Filed: September 19, 2003
    Publication date: July 1, 2004
    Inventors: Su Qian, Donald J Marsh
  • Transgenic mouse expressing non-native wild-type and familial Alzheimer's Disease mutant presenilin 1 protein on native presenilin 1 null background
    Patent number: 6452065
    Abstract: The present invention relates to a transgenic non-human animal embryo lacking native presenilin 1 and a transgenic non-human animal having only a non-native presenilin 1. The transgenic animals and cells derived therefrom can be used in the study of the expression pattern, activity and modulators of presenilin 1, in the study of the role of presenilin 1 in Alzheimer's Disease and in the study of disorders of the central nervous system.
    Type: Grant
    Filed: May 14, 1998
    Date of Patent: September 17, 2002
    Assignees: Merck & Co., Inc., Johns Hopkins University
    Inventors: Hui Zheng, Ping Jiang, Su Qian, Leonardus H. T. Van Der Ploeg, Philip Chun-Ying Wong, Sangram S. Sisodia
  • TRANSGENIC ANIMAL EXPRESSING NON-NATIVE WILD-TYPE AND FAMILIAL ALZHEIMER'S DISEASE MUTANT PRESENILIN 1 PROTEIN ON NATIVE PRESENILIN 1 NULL BACKGROUND
    Publication number: 20020016978
    Abstract: The present invention relates to a transgenic non-human animal embryo lacking native presenilin 1 and a transgenic non-human animal having only a non-native presenilin 1. The transgenic animals and cells derived therefrom can be used in the study of the expression pattern, activity and modulators of presenilin 1, in the study of the role of presenilin 1 in Alzheimer's Disease and in the study of disorders of the central nervous system.
    Type: Application
    Filed: May 14, 1998
    Publication date: February 7, 2002
    Inventors: HUI ZHENG, PING JIANG, SU QIAN, LEONARDUS H. T. VAN DER PLOEG, PHILIP CHUN-YING WONG, SANGRAM S. SISODIA